Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Clinical Oncology is a prestigious peer-reviewed journal published by Elsevier Science London, focusing on the dynamic fields of Oncology and Radiology, Nuclear Medicine, and Imaging. With an impressive impact factor reflecting its high-quality research contributions, the journal is ranked in the second quartile for oncology and the first quartile for radiology, underscoring its importance in advancing clinical knowledge and practice. Established in 1975, Clinical Oncology offers researchers, healthcare professionals, and students robust access to cutting-edge studies, reviews, and clinical trials that drive innovation and improve patient care. Based in the United Kingdom, the journal plays a vital role in disseminating significant findings, fostering collaboration, and enhancing education in the biosciences, particularly for those committed to addressing the challenges in cancer treatment and diagnostics. Given its rigorous selection criteria and broad readership, Clinical Oncology remains an essential resource for anyone dedicated to the fields of oncology and radiology.

YONAGO ACTA MEDICA, published by Tottori University Medical Press, is a prominent journal in the field of Medicine, recognized for its contributions and academic rigor since its inception in 1965. With an ISSN of 0513-5710 and E-ISSN of 1346-8049, this journal is situated in Japan and spans significant periods of convergence from 1965 to 1977 and from 1986 to 2024. Classified within the Q3 category of Medicine (Miscellaneous) and holding a respectable Scopus rank of 275 out of 636 in General Medicine, YONAGO ACTA MEDICA offers an invaluable platform for researchers, professionals, and students to disseminate innovative studies and findings in diverse medical topics. While the journal currently does not operate under an open-access model, it remains committed to promoting academic excellence and advancing medical knowledge through peer-reviewed publications. Address inquiries and contributions to 86 NISHI-CHO, YONAGO, TOTTORI-KEN 683-8503, JAPAN.

The Journal of Adolescent and Young Adult Oncology, published by MARY ANN LIEBERT, INC, is a premier peer-reviewed journal dedicated to enhancing the understanding and treatment of cancers in adolescents and young adults. With an ISSN of 2156-5333 and an E-ISSN of 2156-535X, this journal specializes in providing vital insights into the unique challenges faced by younger cancer patients, promoting research and clinical best practices in this underrepresented population. The journal features a commendable ranking in the Q2 quartile for Oncology and Q1 quartile for Pediatrics, Perinatology, and Child Health—highlighting its impact and relevance in both fields. Its Scopus rankings also reflect a strong standing; positioned at Rank #107/330 in Pediatrics and Rank #225/404 in Oncology. While the journal operates under a subscription-based model, it aims to disseminate crucial research findings and innovative treatments through its engaging content that serves as an invaluable resource for researchers, clinicians, and students alike. Since its inception in 2014, the journal has been at the forefront of addressing the pressing issues pertinent to young cancer patients, making it a vital outlet for groundbreaking studies and clinical advancements within this critical area of healthcare.

Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.

The Southern African Journal of Gynaecological Oncology, published by MEDPHARM PUBLICATIONS PTY LTD, is a leading open-access journal that has been at the forefront of disseminating critical research in the field of gynecological oncology since its inception in 2009. With an ISSN of 2074-2835 and an E-ISSN of 2220-105X, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the nuanced complexities of women's health, particularly in the context of Southern Africa. The journal is dedicated to promoting innovative findings and clinical practices to enhance patient care in gynecological cancer treatment and prevention. Its open-access model ensures that high-quality, peer-reviewed research is readily available to a global audience, fostering collaboration and knowledge sharing within the academic community. As the journal continues to grow, it emphasizes the importance of addressing regional health challenges and advancing the discourse in gynecological oncology.

Oncology Reports is a distinguished journal dedicated to advancing knowledge in the field of oncology. Published by Spandidos Publications Ltd, this journal has been a cornerstone in cancer research since its establishment in 1994 and is set to continue its impactful contributions until 2024. With ISSN 1021-335X and E-ISSN 1791-2431, it ranks in the Q2 category in Cancer Research, Medicine (Miscellaneous), and Oncology as of 2023, reflecting its solid standing in the academic community. The journal's current Scopus rankings position it notably within Medicine (Oncology) (#74/404, 81st percentile) and Biochemistry, Genetics and Molecular Biology (Cancer Research) (#67/230, 71st percentile), underscoring its rigorous peer-review process and the quality of its published research. Although not an open-access journal, Oncology Reports remains committed to disseminating vital information to researchers, professionals, and students, ensuring they stay at the forefront of developments in cancer studies. Its comprehensive scope promotes a multidisciplinary approach, encompassing clinical and experimental aspects of oncology, thus serving as an essential resource for those striving to understand and combat cancer.

Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.